Prediction of BK Virus Reactivation in Kidney Transplant Recipient

Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Jan 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a way to predict the reactivation of a virus called BK virus (BKV) in people who have received a kidney transplant. The BK virus can sometimes cause infections and problems with the new kidney, so being able to predict when it might reactivate could help doctors take action early. The researchers are using a special technique called flow cytometry to examine how the immune system responds to the virus in kidney transplant recipients.

To participate in this trial, individuals must be at least 18 years old and have recently received a kidney transplant from either a living or deceased donor. Participants will need to agree to provide blood samples after their transplant and if they show signs of the virus. However, pregnant individuals and those whose new kidney never started working are not eligible. If you join the study, you can expect to help advance our understanding of BKV and possibly improve care for future kidney transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. New kidney transplantation cases (either living donor or deceased donor transplantation)
• • 2. Age ≥ 18 years old
• • 3. Agree to give a permission to blood sampling post-transplantation, and at the time of BK viremia.
• Exclusion criteria:
• • 1. Pregnant
• • 2. Primary non-function of kidney allograft (i.e. kidney allograft never function).